Bio

Excited to develop life saving biologics at all stages of drug development with hands-on experience from Phase 1 (IND) to Commercialization (BLA/MAA). 7+ years of technical (protein characterization & analytics), management and FDA regulatory experience in dynamic bay area startups and big pharma. Key member of a cross-functional team at Portola Pharmaceuticals which won BLA approval for AndexXa®, a recombinant modified human factor Xa (FXa) protein, and at IGM Biosciences for IND approval of IGM-8444, an anti-Death Receptor 5 IgM antibody. Currently in a growing Protein Analytics and Characterization group at IGM Biosciences developing innovative early and late stage IgM antibodies.